

Melissa Bersanelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5519522/melissa-bersanelli-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

1,732
citations

22
h-index

37
g-index

139
ext. papers

2,407
ext. citations

4.8
avg, IF

5.8
L-index

#	Paper	IF	Citations
117	Renal cell carcinoma and viral infections: A dangerous relationship?. <i>World Journal of Nephrology</i> , 2022 , 11, 1-12	3.6	0
116	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727	3.6	0
115	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. <i>JAMA Oncology</i> , 2021 ,	13.4	11
114	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
113	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302	3.2	1
112	Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211053189	3.2	2
111	The right immune-modulation at the right time: thymosin α 1 for prevention of severe COVID-19 in cancer patients. <i>Future Oncology</i> , 2021 , 17, 1097-1104	3.6	1
110	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103241	7	5
109	Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-6	4.4	2
108	Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103293	7	3
107	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) 2021 , 9,		3
106	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021 , 150, 224-231	7.5	8
105	Pulmonary metastasectomy in renal cell carcinoma: Predictive and prognostic elements from paired histopathological analysis of primary tumors and respective metastases. <i>Journal of Onco-Nephrology</i> , 2021 , 5, 96-104	0.2	
104	Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. <i>Kidney Cancer</i> , 2021 , 5, 93-106	0.6	
103	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3
102	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021 , 142, 18-28	7.5	27
101	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 401-412	3.5	4

100	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281	6.7	5
99	The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient". <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 1930-1934	4.4	6
98	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
97	The gut microbiome and efficacy of cancer immunotherapy. <i>Pharmacology & Therapeutics</i> , 2021 , 231, 107973	13.9	7
96	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
95	Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021 , 155, 315-316	7.5	0
94	Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 396-404	3.3	2
93	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
92	Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211029784	3.2	1
91	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
90	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	1
89	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 491-501	3.5	6
88	The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020 , 43, 196-203	5	16
87	A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?. <i>Anti-Cancer Drugs</i> , 2020 , 31, 211-215	2.4	3
86	Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920915303	5.4	4
85	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 10\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
84	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
83	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 120, 17-26	7.5	41

82	Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 874	59.2	3
81	Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1657-1663	3.6	3
80	Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 515-522	3.6	22
79	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020 , 9, 1710389	7.2	6
78	Baseline and early change of systemic inflammation index (bSII and SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5072-5072	2.2	1
77	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS762-TPS762	2.2	
76	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , 2020 , 12, 59-67	1.8	8
75	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020 , 14, 490	4.3	16
74	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17081-e17081	2.2	
73	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020 , 134, 19-28	7.5	21
72	Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020 , 22, 100161	2	9
71	Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2020 , 21, e65-e73	4.9	2
70	COVID-19 and the newly rediscovered multidisciplinary. <i>Immunotherapy</i> , 2020 , 12, 1101-1103	3.8	3
69	Predictive Ability for Disease-Free Survival of the GGrade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. <i>Current Urology</i> , 2020 , 14, 98-104	1.7	1
68	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
67	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020 , 150, 123-131	5.9	4
66	Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy. <i>Immunotherapy</i> , 2020 , 12, 1139-1148	3.8	6
65	Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond). <i>Lancet Oncology</i> , <i>The</i> , 2020 , 21, 1255-1257	21.7	9

64	Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. <i>Cancers</i> , 2020 , 12,	6.6	38
63	Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. <i>Clinical and Translational Oncology</i> , 2020 , 22, 900-907	3.6	7
62	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 169-185	3.8	10
61	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. <i>Scientific Reports</i> , 2019 , 9, 13218	4.9	9
60	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. <i>Targeted Oncology</i> , 2019 , 14, 247-252	5	10
59	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 87-90	7	15
58	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019 , 24, e327-e337	5.7	80
57	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
56	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 3452762	0.9	5
55	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 237-247.e1	4.9	76
54	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16013-e16013	2.2	1
53	Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab. <i>Acta Biomedica</i> , 2019 , 90, 468-474	3.2	2
52	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2559-2559	2.2	
51	A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. <i>Seminars in Oncology</i> , 2019 , 46, 362-371	5.5	24
50	Family history of cancer and DNA damage response genes: Two sides of the same coin?. <i>Thoracic Cancer</i> , 2019 , 10, 401	3.2	1
49	Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. <i>Immunotherapy</i> , 2019 , 11, 21-35	3.8	11
48	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , 2018 , 10, 643-655	3.8	9
47	Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab. <i>Immunotherapy</i> , 2018 , 10, 743-752	3.8	1

46	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. <i>Medical Oncology</i> , 2018 , 35, 132	3.7	32
45	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
44	Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. <i>Immunotherapy</i> , 2018 , 10, 681-694	3.8	25
43	Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10038-10038	2.2	
42	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018 , 10, 1303-1313	3.8	1
41	Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date. <i>Cancer Management and Research</i> , 2018 , 10, 3773-3780	3.6	3
40	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018 , 38, 5773-5782	2.3	10
39	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
38	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
37	Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts. <i>Journal of Translational Medicine</i> , 2017 , 15,	8.5	78
36	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. <i>European Journal of Cancer</i> , 2017 , 79, 149-151	7.5	8
35	"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?. <i>Lancet Oncology</i> , 2017 , 18, e298	21.7	3
34	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e7-541.e13	2.8	9
33	Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 627-636	5.4	8
32	Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. <i>Annals of Oncology</i> , 2017 , 28, 2747-2753	10.3	20
31	Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 799-806	2.9	16
30	Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?. <i>PLoS ONE</i> , 2017 , 12, e0172341	3.7	2
29	Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient counselling [preliminary analysis of the INVIDIa study. <i>Annals of Oncology</i> , 2017 , 28, xi17	10.3	2

28	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 37-53	2.5	40
27	Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1858-1859	2.2	12
26	Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study. <i>Drugs in R and D</i> , 2017 , 17, 585-596	3.4	7
25	Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder. <i>Tumori</i> , 2017 , 103, 66-71	1.7	4
24	Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14514-e14514	2.2	1
23	Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 494-494	2.2	
22	Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 50-50	2.2	1
21	Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review. <i>Gynecologic and Obstetric Investigation</i> , 2016 , 81, 385-93	2.5	3
20	L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e121-3	8.9	110
19	Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 277-83	3.3	14
18	Non-clear-cell renal carcinoma therapy: handle with care. <i>Lancet Oncology, The</i> , 2016 , 17, 270-271	21.7	3
17	First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16081-e16081	2.2	2
16	Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report. <i>Current Drug Targets</i> , 2016 , 17, 1755-1760	3	9
15	Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2016 , 11, 23-36	4.9	34
14	Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 105-13	15.4	74
13	Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?. <i>Acta Biomedica</i> , 2016 , 87, 224-5	3.2	
12	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
11	Combination therapy in kidney cancer: the next revolution?. <i>Lancet Oncology, The</i> , 2015 , 16, 1441-1442	21.7	6

10	Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2015 , 87, 204-6	5.9	4
9	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?. <i>Lancet Oncology</i> , 2014 , 15, e304	21.7	
8	Lymph node ratio improves TNM and Astler-Coller's assessment of colorectal cancer prognosis: an analysis of 761 node positive cases. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 1824-36	3.3	15
7	Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. <i>Cancers</i> , 2014 , 6, 2035-48	6.6	9
6	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. <i>Anti-Cancer Drugs</i> , 2013 , 24, 535-54	2.4	58
5	Systemic adjuvant therapies in renal cell carcinoma. <i>Oncology Reviews</i> , 2012 , 6, e18	4.3	6
4	Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. <i>Technology in Cancer Research and Treatment</i> , 2012 , 11, 163-7	2.7	9
3	Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. <i>Tumori</i> , 2012 , 98, 594-600	1.7	6
2	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1677-87	3.5	23
1	Endometrial metastasis of lung adenocarcinoma: a case report. <i>Tumori</i> , 2011 , 97, 411-4	1.7	9